Success Metrics

Clinical Success Rate
81.6%

Based on 40 completed trials

Completion Rate
82%(40/49)
Active Trials
3(5%)
Results Posted
55%(22 trials)
Terminated
9(15%)

Phase Distribution

Ph early_phase_1
2
3%
Ph phase_2
11
18%
Ph phase_4
10
16%
Ph phase_3
9
15%
Ph not_applicable
2
3%
Ph phase_1
13
21%

Phase Distribution

15

Early Stage

11

Mid Stage

19

Late Stage

Phase Distribution47 total trials
Early Phase 1First-in-human
2(4.3%)
Phase 1Safety & dosage
13(27.7%)
Phase 2Efficacy & side effects
11(23.4%)
Phase 3Large-scale testing
9(19.1%)
Phase 4Post-market surveillance
10(21.3%)
N/ANon-phased studies
2(4.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

78.4%

40 of 51 finished

Non-Completion Rate

21.6%

11 ended early

Currently Active

3

trials recruiting

Total Trials

62

all time

Status Distribution
Active(3)
Completed(40)
Terminated(11)
Other(8)

Detailed Status

Completed40
Terminated9
unknown8
Recruiting3
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
62
Active
3
Success Rate
81.6%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (4.3%)
Phase 113 (27.7%)
Phase 211 (23.4%)
Phase 39 (19.1%)
Phase 410 (21.3%)
N/A2 (4.3%)

Trials by Status

completed4065%
recruiting35%
unknown813%
terminated915%
withdrawn23%

Recent Activity

Clinical Trials (62)

Showing 20 of 62 trialsScroll for more
NCT07284069Early Phase 1

Senicapoc and Perampanel for Newly Diagnosed Glioblastoma

Recruiting
NCT05915013Phase 1

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response

Recruiting
NCT03196466

Population Pharmacokinetics of Antiepileptic in Pediatrics

Completed
NCT05684978Phase 4

Efficacy and Safety of Perampanel in the Treatment of Refractory Status Epilepticus

Terminated
NCT02307578

An Extended Access Program (EAP) for Perampanel

Unknown
NCT06401707Phase 2

PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest

Recruiting
NCT05533814Phase 4

A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures

Completed
NCT03367533Phase 1

Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response, Pilot Trial

Completed
NCT04497142Phase 1

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

Completed
NCT02914314Phase 2

Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With Epilepsy

Completed
NCT03793868Early Phase 1

Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis

Completed
NCT04309721Phase 3

Perampanel in Focal Status Epilepticus

Terminated
NCT02120365Phase 1

Rapid Determination Of The Clinical Utility Of Perampanel For The Treatment Of Alcohol Dependence

Completed
NCT04202159

A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures

Completed
NCT04650204Phase 4

Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy

Terminated
NCT03020797Not Applicable

A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Terminated
NCT04252846

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Completed
NCT02849626Phase 3

Perampanel as Adjunctive Therapy in Pediatrics With Partial Onset Seizures or Primary Generalized Tonic Clonic Seizures

Completed
NCT05497193

Clinical Efficacy and Safety of Perampanel Monotherapy in the Treatment of Children With Focal Epilepsy

Unknown
NCT03636958Not Applicable

Efficacy and Safety of Perampanel in Combination in Glioma-refractory Epilepsy

Withdrawn

Drug Details

Intervention Type
DRUG
Total Trials
62